LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Point-of-Care Capillary Whole Blood Hematocrit and Hemoglobin Compared

By LabMedica International staff writers
Posted on 14 Jun 2015
Print article
The i-Stat point-of-care system
The i-Stat point-of-care system (Photo courtesy of ABBOTT Corporate)
The clinical suitability of point-of-care devices for conductivity based point-of-care hematocrit with calculated hemoglobin necessitates that they be accurate and that the results are interchangeable with central laboratory methods.

The appropriateness of conductivity based assays in certain patient populations, such as patients on cardiopulmonary bypass and those receiving high volumes of intravenous fluids or autologous blood transfusions, has been questioned.

Clinical laboratory scientists at Massachusetts General Hospital (Boston, MA, USA) performed hematocrit and hemoglobin analysis on 225 clinical samples obtained from intensive care units and the cardiac surgery operating room. All samples were from adult patients over 18 years of age. The samples were first tested for clinical care and then immediately handed off to technologists for the study testing.

The total hemoglobin level was first measured by co-oximetry on the Siemens RAPIDLab 1265 analyzer (Siemens Medical Solutions USA, Inc.; Malvern, PA, USA). Hematocrit and hemoglobin values were obtained on the Abbott i-STAT instrument using one lot of i-STAT E3+ cartridges (Abbott Point of Care; Princeton, NJ, USA). Hemoglobin values from the i-STAT are performed by the calculation of directly measured hematocrit in percent × 0.34. A manual spun hematocrit was performed on each sample as the standard hematocrit reference method. The hematocrit and hemoglobin were also determined on the automated hematology analyzer XE5000 (Sysmex Corporation; Kobe, Japan) by impedance based cumulative pulse height detection and by photometric determination, respectively.

The i-STAT hematocrit and hemoglobin showed close agreement to comparison methods with minimal bias. Median test results were not clinically or statistically different between those measured on the i-STAT and those measured using the manual spun hematocrit reference method or the Sysmex photometric hemoglobin method. The results on the i-STAT were statistically significantly different from those obtained on the Sysmex for hematocrit and the Siemens RAPIDLab co-oximeter for hemoglobin.

The authors concluded that the i-STAT hematocrit and hemoglobin performs well when compared to the hematocrit reference method and other common methods for both hematocrit and hemoglobin. Some differences between non-reference methods may be observed, but these were not considered clinically significant. The study was published in the June 2015 issue of the journal Clinica Chimica Acta.

Related Links:

Massachusetts General Hospital 
Siemens Medical Solutions USA 
Abbott Point of Care 


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit
New
TORCH Infections Test
TORCH Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.